Session: SUN 88-129-Acromegaly & Prolactinoma
Poster Board SUN-121
The goal of this study was to determine the prevalence of clinically silent and completely silent somatotroph adenomas in a large cohort of patients who underwent resection of a pituitary adenoma in our institution.
Design : Review of the pathology reports of patients who underwent resection of pituitary adenomas at a pituitary referral center between 2000 and 2012.
Methods : All pituitary lesions other than adenomas were excluded. We reviewed clinical and biochemical data of patients with adenomas identified by immunohistochemistry as somatotroph adenomas.
Results : A total of 412 patients underwent resection of a pituitary adenoma at Notre-Dame Hospital between January 1, 2000 and June 1, 2012. In 76 of these adenomas, the cell type was somatotroph. Seven patients had adenomas of the silent type, one microadenoma and six macroadenomas. None had any clinical feature of acromegaly preoperatively or when re-examined retrospectively. Only one patient had a clinically silent GH adenoma with a high serum IGF-1 (1083 μg/L). Six patients had a completely silent adenoma (normal IGF-1, mean 223 μg/L, range from 94 to 376 and/or basal GH below 1 μg/L). PRL immunostaining was also present in three, ACTH in two and glycoproteins in one. Silent somatotroph adenomas thus represent 9% of somatotroph adenomas in our series.
Conclusion : Silent somatotroph adenomas may be more prevalent than previously considered.
Disclosure: AL: Investigator, Novartis Pharmaceuticals, Editor, Up To Date, Consultant, Novartis Pharmaceuticals. SV: Investigator, Novartis Pharmaceuticals, Research Funding, Serono. Nothing to Disclose: VP, FB, IB, CB, CG, OS
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters